American Journal of Cardiology最新文献

{"title":"Mechanisms of Cardiac Implantable Electronic Device Interference With the Tricuspid Valve Apparatus","authors":"Karima Addetia MD ,&nbsp;Michael Henry MD ,&nbsp;Heather Smith MD ,&nbsp;Megan Yamat RDCS ,&nbsp;Gene Kim MD ,&nbsp;Renuka Jain MD ,&nbsp;Eisha Wali MD ,&nbsp;Linda Lee MD ,&nbsp;Nathan Marzlin MD ,&nbsp;AbdulRahman Abutaleb MD ,&nbsp;Jonathan Crouch MD ,&nbsp;Eric S. Weiss MD ,&nbsp;Takeyoshi Ota MD ,&nbsp;Christopher Salerno MD ,&nbsp;Huihua Li MD ,&nbsp;Aliya A. Husain MD ,&nbsp;Valluvan Jeevanandam MD ,&nbsp;Roberto M. Lang MD","doi":"10.1016/j.amjcard.2025.04.016","DOIUrl":"10.1016/j.amjcard.2025.04.016","url":null,"abstract":"<div><div>Cardiac implantable electronic devices (CIEDs) have been implicated in the development of tricuspid valve (TV) dysfunction. However, the mechanisms of dysfunction are not well characterized. We sought to define the prevalence, location and mechanisms of CIED-TV interference based on direct inspection of gross pathologic specimens from consecutive patients with CIEDs who had undergone orthotopic heart transplantation (OHT). CIED-interference was classified by location (septal, posterior or anterior trigone of the RV), portion of TV apparatus involved (leaflet(s) only, sub-tricuspid apparatus (STA) only or a combination of both leaflet and STA) and type of interference (adherence, trapping or both). Sixty-two cases of CIED-TV interference were identified (5 leaflet, 30 STA and 27 leaflet and STA). The majority of patients had nonischemic cardiomyopathy (81%) and leads in situ for &lt;10 years (77%). Most CIED-TV interference involved either the posterior (<em>n</em> = 23, 37%), septal (<em>n</em> = 15, 24%) or posteroseptal regions of the RV (<em>n</em> = 16, 26%). Interference with the anterior leaflet or anterior STA was rare. STA interference consisted of lead trapping behind the papillary muscles or chordae alone (<em>n</em> = 6), lead adherence with trapping (<em>n</em> = 21) and lead adherence alone (<em>n</em> = 3). Combination STA and leaflet interference consisted of adherence and trapping (<em>n</em> = 20) and adherence without trapping (<em>n</em> = 7). In conclusion, CIED-TV interference occurs most frequently with the STA in the posterior and septal regions of the RV. These findings have the potential to instruct imagers on how to evaluate for CIED-TV interference in an era where, elucidating the mechanism of TV dysfunction and considering options for repair is gaining momentum.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"250 ","pages":"Pages 30-37"},"PeriodicalIF":2.3,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHA2DS2-VASc Score in Patients With Atrial Fibrillation and Cancer: A U.S. Nationwide Study","authors":"Mohammad AL Mouslmani MD, MPH ,&nbsp;Mohamad Alhoda Alahmad MD ,&nbsp;Zafer Akman MD ,&nbsp;Raiza Rossi MD ,&nbsp;Mufti Rahman MD, MSc, MPH ,&nbsp;Michael G. Nanna MD, MHS","doi":"10.1016/j.amjcard.2025.04.025","DOIUrl":"10.1016/j.amjcard.2025.04.025","url":null,"abstract":"<div><div>The CHA₂DS₂-VASc score is widely accepted as the most reliable tool for risk stratification to guide the initiation of anticoagulation in patients with atrial fibrillation/flutter. However, it has not been validated for use in patients with malignancy, and lacks cancer-related parameters. We aimed to evaluate the CHA₂DS₂-VASc score’s association with acute cerebrovascular accident (CVA) in cancer patients during hospitalization for atrial fibrillation/flutter in the United States. We conducted a cross-sectional analysis of the Nationwide Readmissions Database (NRD) from 2016 to 2019, extracting all cases with a primary diagnosis of atrial fibrillation/flutter. We then divided all patients based on the presence or absence of malignancy and calculated CHA₂DS₂-VASc scores. We identified 1,769,603 weighted admissions with atrial fibrillation/flutter, of those, 96,982 had malignancy. The cohort with malignancy had a mean age of 74 years (SD, 13.4) vs 70.4 years (SD, 17.8). In both cohorts, each additional point in the CHA₂DS₂-VASc score was associated with higher odds of acute CVA during index hospitalization. For the cohort with malignancy, a score of 2 (compared to 0) was associated with an odds ratio (OR) of 4.73 (1.71 to 13.10) compared with 2.61 (2.08 to 3.27) for the cohort without malignancy. In conclusion, the CHA₂DS₂-VASc score was linearly associated with acute CVA in patients with atrial fibrillation/flutter with and without cancer. However, the odds ratios were higher in the cohort with malignancy, emphasizing the importance of anticoagulation initiation in patients with cancer.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"249 ","pages":"Pages 59-64"},"PeriodicalIF":2.3,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143946708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors and Mechanisms of Nonculprit Plaque Progression in Patients With Acute Coronary Syndromes: An In-Vivo Serial Optical Coherence Tomography Study","authors":"Yishuo Xu MD ,&nbsp;Jianlin Ma MD ,&nbsp;Luping He MD, PHD ,&nbsp;Dirui Zhang MD ,&nbsp;Boling Yi MD ,&nbsp;Yan Zuo MD ,&nbsp;Yuhan Qin MD, PHD ,&nbsp;Chen Zhao MD ,&nbsp;Ziqian Weng MD, PHD ,&nbsp;Yanli Sun MD, PHD ,&nbsp;Ming Zeng MD ,&nbsp;Xi Chen MD ,&nbsp;Ning Wang MD ,&nbsp;Xue Feng MD, PHD ,&nbsp;Yue Zhu MD ,&nbsp;Wei Hao MD ,&nbsp;Lulu Li MS ,&nbsp;Huai Yu MD, PHD ,&nbsp;Yini Wang MD, PHD ,&nbsp;Sining Hu MD, PHD ,&nbsp;Bo Yu MD, PHD","doi":"10.1016/j.amjcard.2025.04.023","DOIUrl":"10.1016/j.amjcard.2025.04.023","url":null,"abstract":"<div><div>Plaque progression is vital in the relationship between baseline phenotypes and future adverse events. Serial optical coherence tomography (OCT) has enabled the comprehensive assessment of plaque progression in vivo. This study aimed to explore the predictors of nonculprit plaque progression in patients with acute coronary syndrome (ACS) and assess the underlying mechanisms of progression using serial OCT. Patients diagnosed with ACS who underwent baseline and 12 ± 3 months of follow-up OCT scans between September 2013 and August 2022 were retrospectively enrolled. OCT defined plaque progression as a reduction in minimal lumen area of ≥0.84 mm² at follow-up. A total of 406 patients with ACS and 1,054 nonculprit plaques met the inclusion criteria, with a median follow-up duration of 369 days. Lesion location, luminal severity and the prevalence of vulnerable features significantly differed between the progression and nonprogression groups. In the multivariate analysis, thin-cap fibroatheroma (TCFA) (OR: 2.028, 95% CI: 1.287 to 3.196), macrophages (OR: 1.919, 95% CI: 1.212 to 3.040), microchannels (OR: 1.941, 95% CI: 1.353-2.782), and layered plaques (OR: 1.660, 95% CI: 1.178 to 2.339) were independent predictors of plaque progression. Two mechanisms of lesion progression were observed: Type I (54.6%): lesion progression without silent event(s). Type II (45.4%): lesion progression accompanied by silent event(s), including new layer formation and/or new intra-plaque hemorrhage. In conclusion, TCFA, macrophages, microchannels, and layered plaques independently predict nonculprit plaque progression in patients with ACS. Serial OCT examinations can identify distinct mechanisms of plaque progression that vary dramatically among different plaque phenotypes.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"249 ","pages":"Pages 19-28"},"PeriodicalIF":2.3,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Pressure-Derived Physiologic Indices and Inducible Myocardial Ischemia During the Adenosine Stress Test","authors":"Do-Yoon Kang MD ,&nbsp;Ji Sung Lee PhD ,&nbsp;Cheol Whan Lee MD","doi":"10.1016/j.amjcard.2025.04.024","DOIUrl":"10.1016/j.amjcard.2025.04.024","url":null,"abstract":"<div><div>We evaluated the relationship between pressure-derived physiologic indices and inducible myocardial ischemia (IMI), defined by significant ST-segment changes during adenosine stress testing, in 227 patients with left main or left anterior descending coronary artery disease. Associations with symptomatic improvement, assessed by the 7-item Seattle Angina Questionnaire at 1 month post-PCI, were also analyzed. Optimal cut-off values for IMI were lower than current thresholds, with the instantaneous wavefree ratio (iFR) showing superior diagnostic accuracy (higher AUC) compared to other indices. PCI provided the greatest symptomatic relief in patients with moderate-to-severe angina and concomitant IMI. In conclusion, iFR more accurately identifies IMI, and PCI benefits are most pronounced in patients with IMI-related chest pain.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"250 ","pages":"Pages 17-19"},"PeriodicalIF":2.3,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Coronary Intervention or Minimally Invasive Coronary Bypass for Isolated Left Anterior Descending Artery Disease","authors":"Alan Gallingani ,&nbsp;Giulia Pampuri ,&nbsp;Nadim Diab ,&nbsp;Giulia Grassa ,&nbsp;Daniel Hernandez-Vaquero ,&nbsp;Domenico Tuttolomondo ,&nbsp;Davide Carino ,&nbsp;Gurmeet Singh ,&nbsp;Francesco Nicolini ,&nbsp;Francesco Formica","doi":"10.1016/j.amjcard.2025.04.014","DOIUrl":"10.1016/j.amjcard.2025.04.014","url":null,"abstract":"<div><div>The optimal revascularization strategy for isolated left anterior descending (LAD) artery disease, minimally invasive direct coronary artery bypass (MIDCAB) and percutaneous coronary intervention (PCI), remains a subject of debate. This updated meta-analysis aimed to compare the long-term outcomes of MIDCAB versus PCI for patients with isolated LAD artery disease. Three databases were systematically searched to identify randomized controlled trials (RCTs) and adjusted studies. Primary outcomes included long-term survival and repeat target vessel revascularization (TVR). The secondary endpoint was long-term major adverse cardiovascular events (MACEs). Hazards ratios (HR) and Confidence Intervals (CI) were calculated for long-term outcomes and a random effects model was used. Sensitivity analyses included subgroups analysis of stent-type. Nine articles, comprising 4 RCTs, totaling 2,168 patients (MIDCAB = 1,086 and PCI = 1,080) were included. The weighted mean follow-up was 4.35 ± 4.9 years. Long-term survival was comparable between MIDCAB and PCI (HR = 0.76; 95% CI, 0.58 to 1.00; p = 0.05). MIDCAB was associated with a significantly lower rate of repeat TVR (HR = 0.35; 95% CI, 0.25 to 0.49; p &lt;0.0001) and a reduced risk of MACEs (HR = 0.59; 95% CI, 0.43 to 0.81; p &lt;0.0001), although the difference was not evident in subgroup analysis comparing MIDCAB and PCI with drug-eluting stent (HR = 0.66; 95% CI, 0.46 to 1.06; p = 0.09). In conclusion, this meta-analysis of RCTs and adjusted studies shows that in patients with isolated LAD lesion, MIDCAB and PCI exhibit comparable long-term survival. However, MIDCAB is associated with a significantly reduced risk of long-term repeat TVR and MACEs compared to PCI.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"249 ","pages":"Pages 36-42"},"PeriodicalIF":2.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Pregnancy in Women With Congenitally Corrected Transposition of the Great Arteries: A Systematic Review","authors":"Jena Pizula MD ,&nbsp;Nare Torosyan MD ,&nbsp;Sarah Solimon MD ,&nbsp;Jenica Thangathurai MD ,&nbsp;Anil Mehra MD ,&nbsp;Amy Chatfield MLS ,&nbsp;Uri Elkayam MD","doi":"10.1016/j.amjcard.2025.03.021","DOIUrl":"10.1016/j.amjcard.2025.03.021","url":null,"abstract":"<div><div>Congenitally corrected transposition of the great arteries (ccTGA or L-TGA) presents potentially challenging cardiac physiology in the pregnant state. While women with ccTGA often live into childbearing age, little is known about the maternal and fetal outcomes of pregnancy in this rare and heterogenous patient population. We performed a systematic review of the literature over the last 25 years to further investigate these outcomes. A total of 107 women who had 178 pregnancies were analyzed. Maternal outcomes demonstrated: mortality (0.6%), hospitalization (24.5%), heart failure (9.6%) and arrythmia (11.2%). Fetal outcomes included live birth (83.6 %), premature deliveries (10.2%), cesarian section (44.6%), and congenital heart disease identified in offspring (1.9%). Overall mortality was low but high rates of hospitalization highlight the importance of monitoring for potential morbidity and complication in this patient population. While this is the largest review to date on maternal and fetal outcomes in pregnancy in women with ccTGA, future studies are warranted to augment our understanding of cardiovascular and obstetrical outcomes in this population.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"250 ","pages":"Pages 9-16"},"PeriodicalIF":2.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Compact Myocardial Thinning in Patients with Left Ventricular Noncompaction","authors":"Tea Gegenava MD, PhD ,&nbsp;Martijn Tukker MD, PhD ,&nbsp;Kadir Caliskan MD, PhD ,&nbsp;Alexander Hirsch MD, PhD ,&nbsp;Ashish Manohar PhD ,&nbsp;Seung-Pyo Lee MD, PhD ,&nbsp;Anjali Owens MD ,&nbsp;Deborah H. Kwon MD ,&nbsp;Jay Ramchand MD, PhD ,&nbsp;Matthew T. Wheeler MD, PhD ,&nbsp;W.H. Wilson Tang MD ,&nbsp;Koen Nieman MD, PhD","doi":"10.1016/j.amjcard.2025.04.018","DOIUrl":"10.1016/j.amjcard.2025.04.018","url":null,"abstract":"<div><div>Clinical presentations of left ventricular noncompaction (LVNC) range from asymptomatic cases to ventricular tachyarrhythmia (VT), heart failure (HF), and cerebrovascular accidents (CVA). In this multicenter study, we explored the associations between clinical and imaging characteristics and outcomes of LVNC patients and validated the predictive value of myocardial thinning identified on cardiac magnetic resonance imaging (CMR) as previously described. About 214 adult patients (54% male, mean age 41 ± 16 years) meeting the imaging criteria for LVNC were identified. Myocardial thinning was defined as a 50% or greater diameter reduction of the compacted myocardium compared to a contiguous segment on CMR. The primary endpoint was the occurrence of a major adverse cardiovascular event (MACE), defined as a composite of all-cause mortality, HF hospitalization, left ventricular assist device (LVAD) or heart transplant, cardiac resynchronization therapy (CRT), CVA/transient ischemic attacks (TIA), VT and appropriate implantable cardioverter defibrillator (ICD) therapy. Focal myocardial thinning was observed in 42 patients (20%). Over a median follow-up time of 7 years (IQR, 4 to 10 years), 54 patients (24%) experienced a primary outcome. Patients with myocardial thinning had more cumulative adverse events than those without myocardial thinning (chi-square = 29.516, log-rank &lt; 0.001), even after matching for medical risk score. In a multivariate Cox regression model, myocardial thinning remained associated with outcomes: HR 3.052 (95% CI: 1.569 to 5.937, p = 0.001). Myocardial thinning is associated with adverse cardiovascular events in LVNC patients. Incorporating myocardial thinning into medical risk assessments can improve the prediction and management of adverse outcomes in these patients.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"249 ","pages":"Pages 51-58"},"PeriodicalIF":2.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials","authors":"Ibrahim Khalil MBBS ,&nbsp;Mohd Turzo Rahman MD ,&nbsp;Imran Hossain MBBS","doi":"10.1016/j.amjcard.2025.04.013","DOIUrl":"10.1016/j.amjcard.2025.04.013","url":null,"abstract":"<div><div>Hyperlipidemia is one of the most prominent risk factors for heart diseases, and current treatments are sometimes insufficient to control it. Inclisiran, a small interfering RNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), provides a novel, long-acting approach to improve hyperlipidemia. This meta-analysis was conducted following the PRISMA guidelines. A total of 5 out of 185 studies screened met the inclusion criteria. The primary outcome was a reduction in the LDL-C level compared to control group. Statistical analysis used a random-effect model to calculate the mean difference (MD) for with 95% confidence interval (CI). A total of 5 randomized controlled trials comprised 4,072 patients, divided into the Inclisiran arm (<em>n</em> = 2,129) and the Control arm (<em>n</em> = 1,943). Compared with control, this study showed Inclisiran substantially reduces LDL-C (MD, −51.25%; 95% CI, [−56.58 to −45.92], p &lt;0.00001), total cholesterol (MD, −27.75%; 95% CI, [−30.39 to −25.10], p &lt;0.00001), apolipoprotein B (MD, −36.65%; 95% CI, [−45.93 to −27.37], p = 0.00039), triglycerides (MD, −12.39%; 95% CI, [−21.49 to −3.28], p = 0.02275), PCSK9 level (MD, −77.00%; 95% CI, [−86.89 to −67.11], p = 0.00014), and lipoprotein (a) (MD, −21.77%; 95% CI, [−24.29 to −19.24], p = 0.000018). Inclisiran also significantly increases HDL-C levels by a mean difference of +5.86% (MD, 95% CI, [+4.77 to +6.95], p = 0.0001). This meta-analysis demonstrates that Inclisiran significantly improves lipid profiles in hyperlipidemia, reducing LDL-C, total cholesterol, apolipoprotein B, triglycerides, PCSK9, and lipoprotein (a), while increasing HDL-C levels. Its innovative mechanism and twice-yearly dosing enhance efficacy, safety, and patient adherence.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"250 ","pages":"Pages 20-29"},"PeriodicalIF":2.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation and Contrast-Associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention","authors":"Mark Shneyderman BS,&nbsp;Johny Nicolas MD, MSc,&nbsp;Samantha Sartori PhD,&nbsp;Angelo Oliva MD,&nbsp;Yihan Feng MS,&nbsp;Birgit Vogel MD,&nbsp;Benjamin Bay MD,&nbsp;Mauro Gitto MD,&nbsp;Francesca Maria Di Muro MD,&nbsp;Raman Sharma MD,&nbsp;Joseph Sweeny MD,&nbsp;Amit Hooda MD,&nbsp;Samin K. Sharma MD,&nbsp;George D. Dangas MD, PhD,&nbsp;Annapoorna S. Kini MD,&nbsp;Roxana Mehran MD","doi":"10.1016/j.amjcard.2025.04.021","DOIUrl":"10.1016/j.amjcard.2025.04.021","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"249 ","pages":"Pages 68-70"},"PeriodicalIF":2.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of Digital Smart Care in the Management of Systemic Hypertension","authors":"Nataliya Kasimovskaya PhD,&nbsp;Mariya Krivetskaya MSc,&nbsp;Natalia Geraskina MSc,&nbsp;Nina Ulianova MSc,&nbsp;Ekaterina Chalova MSc,&nbsp;Anastasia Shushpanova MSc","doi":"10.1016/j.amjcard.2025.04.010","DOIUrl":"10.1016/j.amjcard.2025.04.010","url":null,"abstract":"<div><div>The study aims to determine the effectiveness of a digital smart care model for patients with Systemic Hypertension (SH) compared to traditional care methods. Conducted from January 2022 to December 2024 in Moscow, Russia, the study involved 3 medical organizations and 800 participants randomly divided into 2 groups: 1 utilizing the digital smart care model and a control group following traditional care methods. Patients were surveyed using the SF-36 and EQ-5D questionnaires, along with patient satisfaction surveys and physician satisfaction assessments. The study revealed a statistically significant improvement in health indicators for the group using the digital smart care model compared to traditional methods. Specifically, average blood pressure levels decreased by 10% in the digital care model group, while patient satisfaction increased by 15%. These results indicate the effectiveness of the digital smart care model in enhancing the health and satisfaction of patients with SH. In conclusion, this highlights the potential of digital technologies in medical practice to improve care quality and enhance treatment outcomes for patients with SH.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"250 ","pages":"Pages 1-8"},"PeriodicalIF":2.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}